

BioRestorative Therapies, Inc.  
 Form 4  
 February 15, 2017

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2015  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
 Silva Francisco

2. Issuer Name and Ticker or Trading Symbol  
 BioRestorative Therapies, Inc.  
 [BRTX]

5. Relationship of Reporting Person(s) to Issuer  
 (Check all applicable)

(Last) (First) (Middle)  
 40 MARCUS DRIVE  
 (Street)

3. Date of Earliest Transaction  
 (Month/Day/Year)  
 02/14/2017

\_\_\_\_ Director  
 Officer (give title below) \_\_\_\_\_ 10% Owner  
 \_\_\_\_\_ Other (specify below)  
 VP of Research and Development

MELVILLE, NY 11747  
 (City) (State) (Zip)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership Indirect Beneficial Ownership (Instr. 4) |     |       |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|---|-----|-------|
|                                 |                                      |  |                                | (A) or (D)  | Code  | V  | Amount  | (D) | Price |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
 (9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

| 1. Title of Derivative Security | 2. Conversion or Exercise | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any | 4. Transaction Code | 5. Number of Derivative Securities Acquired | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Security (Instr. 3 and 4) |
|---------------------------------|---------------------------|--------------------------------------|-----------------------------------|---------------------|---|--|---|
|---------------------------------|---------------------------|--------------------------------------|-----------------------------------|---------------------|---|--|---|

Edgar Filing: BioRestorative Therapies, Inc. - Form 4

| (Instr. 3)   | Price of Derivative Security | (Month/Day/Year) | (Instr. 8) |   | (A) or Disposed of (D) (Instr. 3, 4, and 5) |            | Date Exercisable | Expiration Date | Title        | Amount or Number of Shares |
|--------------|------------------------------|------------------|------------|---|---|------------|------------------|-----------------|--------------|----------------------------|
|              |                              |                  | Code       | V | (A)   | (D)        |                  |                 |              |                            |
| Stock Option | \$ 10                        | 02/14/2017       | D          |   | 4,000                                       |            | <u>(1)</u>       | 04/04/2021      | Common Stock | 4,000                      |
| Stock Option | \$ 4.7                       | 02/14/2017       | A          |   | 4,000                                       |            | <u>(1)</u>       | 04/04/2021      | Common Stock | 4,000                      |
| Stock Option | \$ 25                        | 02/14/2017       | D          |   | 150   | 06/24/2011 |                  | 06/23/2021      | Common Stock | 150                        |
| Stock Option | \$ 4.7                       | 02/14/2017       | A          |   | 150   | 06/24/2011 |                  | 06/23/2021      | Common Stock | 150                        |
| Stock Option | \$ 20                        | 02/14/2017       | D          |   | 1,000                                       | 11/16/2011 |                  | 11/15/2021      | Common Stock | 1,000                      |
| Stock Option | \$ 4.7                       | 02/14/2017       | A          |   | 1,000                                       | 11/16/2011 |                  | 11/15/2021      | Common Stock | 1,000                      |
| Stock Option | \$ 21                        | 02/14/2017       | D          |   | 2,000                                       |            | <u>(2)</u>       | 02/09/2022      | Common Stock | 2,000                      |
| Stock Option | \$ 4.7                       | 02/14/2017       | A          |   | 2,000                                       |            | <u>(2)</u>       | 02/09/2022      | Common Stock | 2,000                      |
| Stock Option | \$ 28                        | 02/14/2017       | D          |   | 5,500                                       |            | <u>(3)</u>       | 05/02/2022      | Common Stock | 5,500                      |
| Stock Option | \$ 4.7                       | 02/14/2017       | A          |   | 5,500                                       |            | <u>(3)</u>       | 05/02/2022      | Common Stock | 5,500                      |
| Stock Option | \$ 30                        | 02/14/2017       | D          |   | 4,000                                       |            | <u>(4)</u>       | 12/07/2022      | Common Stock | 4,000                      |
| Stock Option | \$ 4.7                       | 02/14/2017       | A          |   | 4,000                                       |            | <u>(4)</u>       | 12/07/2022      | Common Stock | 4,000                      |
| Stock Option | \$ 12                        | 02/14/2017       | D          |   | 5,000                                       |            | <u>(5)</u>       | 10/04/2023      | Common Stock | 5,000                      |
| Stock Option | \$ 4.7                       | 02/14/2017       | A          |   | 5,000                                       |            | <u>(5)</u>       | 10/04/2023      | Common Stock | 5,000                      |
| Stock Option | \$ 13                        | 02/14/2017       | D          |   | 12,500                                      |            | <u>(6)</u>       | 02/18/2024      | Common Stock | 12,500                     |
| Stock Option | \$ 4.7                       | 02/14/2017       | A          |   | 12,500                                      |            | <u>(6)</u>       | 02/18/2024      | Common Stock | 12,500                     |
| Stock Option | \$ 10.6                      | 02/14/2017       | D          |   | 2,000                                       | 03/12/2014 |                  | 03/11/2024      | Common Stock | 2,000                      |
| Stock Option | \$ 4.7                       | 02/14/2017       | A          |   | 2,000                                       | 03/12/2014 |                  | 03/11/2024      | Common Stock | 2,000                      |

Edgar Filing: BioRestorative Therapies, Inc. - Form 4

|              |         |            |  |   |        |            |            |              |        |
|--------------|---------|------------|--|---|--------|------------|------------|--------------|--------|
| Stock Option | \$ 28   | 02/14/2017 |  | D | 2,000  | 04/14/2014 | 05/02/2022 | Common Stock | 2,000  |
| Stock Option | \$ 4.7  | 02/14/2017 |  | A | 2,000  | 04/14/2014 | 05/02/2022 | Common Stock | 2,000  |
| Stock Option | \$ 6.6  | 02/14/2017 |  | D | 37,500 | (7)        | 10/23/2024 | Common Stock | 37,500 |
| Stock Option | \$ 4.7  | 02/14/2017 |  | A | 37,500 | (7)        | 10/23/2024 | Common Stock | 37,500 |
| Stock Option | \$ 7    | 02/14/2017 |  | D | 25,000 | (8)        | 09/04/2025 | Common Stock | 25,000 |
| Stock Option | \$ 4.7  | 02/14/2017 |  | A | 25,000 | (8)        | 09/04/2025 | Common Stock | 25,000 |
| Stock Option | \$ 3.73 |            |  |   |        | (9)        | 06/10/2026 | Common Stock | 60,000 |

## Reporting Owners

| Reporting Owner Name / Address                           | Relationships |           |                                |       |
|--|---------------|-----------|--------------------------------|-------|
|  | Director      | 10% Owner | Officer                        | Other |
| Silva Francisco<br>40 MARCUS DRIVE<br>MELVILLE, NY 11747 |               |           | VP of Research and Development |       |

## Signatures

/s/ Francisco Silva  
02/14/2017

\*\*Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option is exercisable to the extent of 2,000 shares on each of April 5, 2011 and April 5, 2012.
- (2) The option is exercisable to the extent of 1,000 shares on each of February 10, 2012 and February 10, 2013.  
The option is exercisable to the extent of 500 shares on each of May 3, 2013, May 3, 2014 and May 3, 2015, became exercisable to the extent of 1,000 shares based on the satisfaction of certain conditions and is exercisable to the extent of 3,000 shares subject to the satisfaction of certain conditions.
- (3) The option is exercisable to the extent of 2,000 shares on each of December 7, 2012 and December 7, 2013.
- (4) The option is exercisable to the extent of 2,500 shares on each of October 4, 2013 and October 4, 2014.
- (5) The option is exercisable to the extent of 4,167 shares on each of February 18, 2014 and February 18, 2015, and 4,166 shares on February 18, 2016.
- (6) The option is exercisable to the extent of 12,500 shares on each of October 23, 2015, October 23, 2016 and October 23, 2017.
- (7) The option is exercisable to the extent of 8,334 shares on September 4, 2016 and 8,333 shares on each of September 4, 2017 and September 4, 2018.
- (8)

## Edgar Filing: BioRestorative Therapies, Inc. - Form 4

- (9) The option is exercisable to the extent of 20,000 shares on each of June 10, 2017, June 10, 2018 and June 10, 2019.
- (10) The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.